Trials / Completed
CompletedNCT02377999
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An exploratory open label, single treatment trial of anogenital warts with Picato® repeated up to 2 times with two weeks intervals.
Detailed description
The purpose of the present trial is to explore the safety, tolerability and efficacy when treating GW with Picato® 0.05% gel. The primary outcome measures will be related to safety and tolerability and consists of severity of any local reactions in the treated area; treatment-related adverse events (AEs) and serious AEs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Picato |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2015-03-04
- Last updated
- 2025-02-24
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02377999. Inclusion in this directory is not an endorsement.